News Portal

trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™

Suicide Prevention Company Leverages Brain-Immune Connection to Tackle 54 Billion Dollar Gambling Addiction Epidemic


https://www.prnewswire.com/news-release ... 35601.html


ELK CITY, Idaho, Feb. 25, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today positive preliminary data from its ongoing Federally Registered clinical trial entitled "Validation of Kaihani Score for Gambling Addiction1".

Preliminary data revealed a profound increase in the neuromodulatory protein assessed by Kaihani Score™ which correlated with gambling addiction severity. Four patients with no gambling addiction had 13.4±1.6 ng/ml, four patients with moderate gambling addiction had 37.4±5.6 ng/ml, and four patients with several gambling addiction had 57.7±6.3 ng/ml. Severity of gambling addiction was assessed using Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS). The clinical study needs to recruit another 6 patients per group for completion.

"These preliminary results strongly support our overarching concept that the immune system can be utilized as a stethoscope for the brain" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "It is our aim at Campbell Neurosciences to elucidate the biological basis of mental illnesses, and using this knowledge to develop cures, not band-aid drugs."

Campbell Neurosciences, a spin-off of the biotherapeutics company Therapeutic Solutions International is named after Kathleen Campbell, mother of Kalina O'Connor, who was a victim of suicide.

"In contrast to the Campbell Score™, which assesses inflammatory markers as a means of diagnosing suicidal ideations, the Kaihani Score™ assesses specific neuromodulatory peptides made by the brains of gambling addicts" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "This completely different nature of the cytokines involved suggest the existence of complicated neuroimmune circuits. Our mission at Campbell is to decipher these circuits and develop practical interventions."

"This is a significant milestone in the treatment of gambling addiction, which is estimated according to economists to take a $54 billion annual toll on our economy2" stated Wais Kaihani, co-inventor of the Kaihani score and consultant to the Company.

"As a clinical stage cancer immunotherapy company, we see the potent effects of the immune system on the nervous system in our various preclinical and clinical studies" said Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Inventor of the Kaihani Score™. "Gambling addiction is a significant problem for which no medical interventions or even proper diagnosis exists. I congratulate Ms. O'Connor and her team for scientifically and expediently addressing this major affliction on our society."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Validation of Kaihani Score for Gambling Addiction - Full Text View - ClinicalTrials.gov
2 Social costs of gambling nearly half that of drug abuse, new book concludes | Archives | News Bureau | University of Illinois

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Approved by Amazon to sell its highly regarded immune supplement QuadraMune™ along with other brands.

A milestone accomplishment by the new Therapeutic Solutions sales and marketing department


https://www.prnewswire.com/news-release ... 36416.html

ELK CITY, Idaho, Feb. 26, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the approval to market our dietary supplements on the Amazon e-commerce platform.

Amazon.com is an international e-commerce company offering online retail shopping as well as other services. According to recent industry figures, Amazon is the leading e-retailer in the United States with close to 280.5 billion U.S. dollars in 2019 net sales.

"I am very excited on this first step for TSOI sales, it is the beginning of many more to infiltrate all of the potential markets for our products. I want to make sure everyone has access and can find TSOI products everywhere," said Serena Robella, Director of Sales for the Company. "My personal favorite is QuadraMune and I can't live without it. Once you take it, you won't be able to either."

The initial products to be offered will be NanoStilbene™, ProJuvenol™, and QuadraMune™. As new products are commercialized, they will be added to this initial offering of these three, our most popular supplements.

"We couldn't be more excited about this than we are right now, and I am so thrilled with the work that Serena did to accomplish this incredible opportunity to offer our cutting-edge nutraceuticals to the Amazon community," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Amazon has 100's of millions of shoppers monthly and I know Serena will take full advantage of all the tools available on the platform to rapidly increase our sales."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

CONTACT: ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Approved on RangeMe to sell QuadraMune™ and NanoStilbene™ along with other supplements

RangeMe is the leading product discovery and sourcing platform where retailers and suppliers discover, connect, and grow their business


https://www.prnewswire.com/news-release ... 39566.html


ELK CITY, Idaho, March 3, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today the approval to market our dietary supplements on the RangeMe B2B platform.

RangeMe.com is an online platform that enables retail buyers to efficiently discover innovative and emerging products while empowering suppliers to manage and grow their brands with the tools, insights, and services they need. With 10,000+ Retail buyers our products are now placed in front of them in our category of dietary supplements and nutraceuticals.

"This is another major step for TSOI sales as we continue to penetrate all of the potential markets we can for our products," said Serena Robella, Director of Sales for the Company. "Buyers who are interested in our products can now connect with us directly on RangeMe to initiate discussions about adding our line to their stores and I anxiously await that first contact."

The initial products to be offered will be NanoStilbeneä, ProJuvenolä, QuadraMuneä and NanoPSA. As new products are commercialized, they will be added to this initial offering of these four, our most popular supplements.

"Serena is firing on all cylinders right now and we are excited about the potential of this new market for the Company and so a big congratulations to her are in order," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Last week we announced being accepted on the Amazon platform and now we have added the potential for brick-and-mortar Nationwide."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention

"First in Class" Therapy Reduces Suicide Associated Biological Pathways in Preclinical Studies


https://www.prnewswire.com/news-release ... 40517.html


ELK CITY, Idaho, March 4, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical results and filing of a patent covering the use of manipulated cord blood derived monocytes for prevention of suicidal ideations as well as inflammation of the brain. Company scientists found that administration of non-stem cell components of cord blood to mice exposed to brain inflammation resulted in protection of neurological function as well as suppression of immunological proteins associated in humans with suicidal thoughts.

Paradoxically, it was found that the monocyte component of cord blood was associated with therapeutic activity. Monocytes are typically inflammation inducing cells. Through a trial and error process, the Company found oxytocin pretreatment under proprietary conditions resulted in protection of neurological function (Morris Water Maze) and reduction of inflammation in preclinical studies.

"The fact that the fetus is not immunologically rejected by the mother, despite being genetically incompatible is still largely unexplained," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "We believe that these monocytes possess unique properties that stop the mother's immune system from rejecting the offspring. The data suggests that these same properties may be harnessed to stop inflammation of the brain, which predisposes to suicide."

"While great advances have been made in development of small molecule drugs, there is a growing appreciation for new cell therapies. A recent example is the >$150 million capital raise for a preclinical stage cellular immunotherapy company,1" stated Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "Given easy access to cord blood and economical cost of production, we are eager to continue our preclinical work and advance to FDA IND filing."

"Campbell Neurosciences recently announced positive results of our Campbell Score™ blood based suicidal propensity clinical trial," said Kalina O'Connor, President and Chief Executive Officer of Campbell Neurosciences. "Given that the inflammatory proteins that were reduced in preclinical studies are similar to those assessed by the Campbell Score™ in patients, we are optimistic about clinical translation of this novel approach to preventing suicide."

"The current data and patent filing exemplifies the synergistic relationship between us and our spin-off," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The discovery was facilitated by experimentation during production of StemVacs, our umbilical cord derived cancer vaccine. It was observed that monocytes, which are also used to produce immune stimulatory dendritic cells, can acquire radically different properties based on growth conditions which we control in a proprietary manner. We plan to collaborate closely for clinical translation of this unique approach to a psychiatric condition."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline (prnewswire.com)

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Reports Reduction of Tumor Blood Vessels in Mouse Melanoma Model Treated with StemVacs

Discovery of New Mechanisms of Action Supports Novel Applications for Dendritic Cell Based Cancer Cellular Immunotherapy


https://therapeuticsolutionsint.com/the ... -stemvacs/

ELK CITY, Idaho, March 8, 2021 /TSOINewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today novel findings suggesting that StemVacs treatment induces regression of tumor-feeding blood vessels in a mouse model of melanoma.

StemVacs, which is comprised of allogeneic cord blood derived dendritic cells, has previously been shown to induce anti-tumor immunity and stimulation of natural killer cell activity [1]. The current data supports the notion that StemVacs may not predispose to drug resistance since tumor-feeding blood vessels are not mutating as fast as tumor cells are.

“The findings disclosed today point to a completely new mechanism of action for StemVacs” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “Tumor blood vessels are a unique target in that they do not possess genetic abnormalities like the cancer. This means that if we can attack tumor blood vessels immunologically, we may really have found the Achilles Heel of cancer.”

Dr. Thomas Ichim, Board Member of the Company, and Dr. Francesco Marincola, Scientific Advisory Board Member, previously published that selective immunity to cancer endothelial cells may be achieved while sparing immune attack to healthy endothelium [2]. Furthermore, in a previous company [3], Dr. Ichim obtained an FDA Investigational New Drug clearance to begin treating patients with immunotherapy that specifically targets the blood vessels that feed cancer and keep it alive.

“The field of targeting cancer blood vessels, called “anti-angiogenesis” therapy, is extremely exciting” said Famela Ramos, Vice President of Business Development for the Company. “The drug Avastin, which also targets tumor blood vessels, although not nearly as effective as StemVacs based on animal studies, had $7.2 billion in sales in 2019 [4].

“The mantra at TSOI is that we are a “science first” company” said Timothy Dixon, President and CEO of the Company. “In cases like today’s it really pays off to be a “science first” company because it opens up new possibilities of treatment and new combinations based on elucidation of this novel mechanism of action by which StemVacs appears to be functioning.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 https://www.biospace.com/article/releas ... -to-cancer
2 https://translational-medicine.biomedce ... 015-0688-5
3 https://www.businesswire.com/news/home/ ... unotherapy
4 https://www.fiercepharma.com/special-re ... 19-avastin
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™

Company Generates Stem Cell Derived Cancer "Super-Killers" by Combining Inducible Pluripotent Stem Cell Technology with Gene Silencing and NIH Discovered Universal Tumor Antigen


https://www.prnewswire.com/news-release ... 48331.html

ELK CITY, Idaho, March 16, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent and new data covering what the Company believes to be the first gene-modified, stem cell derived, universal donor dendritic cell cancer immunotherapy.

The novel product, StemVacs-V™, is derived from a gene-modified stem cell which is designed to express proteins found selectively in cancer such as the antigen Brother of the Regulatory of Imprinted Sites (BORIS). Additionally, the stem cell is gene silenced for receptors which cancer generally uses to block immune cell activation. Once the stem cells are made into dendritic cells, the resulting product is an immunotherapy that: 1) Activates the immune system to selectively kill cancer, without toxicity; and 2) Is resistant to cancer-induced immune suppressive activities; and 3) Can be generated in an economical, reproducible, and consistent manner.

"Today's discovery allows us to take everything we learned through our StemVacs™ dendritic cell cancer immunotherapy program and apply it to a radically new and powerful way of treating cancer," said Dr. James Veltmeyer, Chief Medical Officer of the Company and Top Doctor of San Diego and co-inventor of the patent. "By growing dendritic cells from inducible pluripotent stem cells, we are taking advantage of the consistency that is only possible through pluripotent stem cells. By modifying the stem cells so that the resulting dendritic cells are resistant to cancer-secreted immune suppressive molecules, we are creating a novel approach to immunotherapy that to my knowledge has not been attempted outside our team."

The Company previously treated 10 cancer patients using StemVacs dendritic cells and demonstrating augmentation of natural killer cell activity1. The Company now aims to clinically develop StemVacs-V™, which is an iPSC-derived dendritic cell that is specifically engineered to attack cancer. The BORIS antigen, which was utilized by the Company in preclinical studies has been demonstrated by scientists at the National Institutes of Health (NIH), together with Company Board Member, Dr. Thomas Ichim, to function as a "universal cancer vaccine2,3."

"iPSC-based NK-cell and T-cell immunotherapies are at the forefront of innovation in one of science's most cutting-edge and well-funded fields. This explains why we are seeing near and above billion-dollar valuations for companies in this space that are in late preclinical/early clinical stages of development," said Famela Ramos, the Company's Vice President of Business Development and co-inventor of the patent. "We believe that by targeting dendritic cells, which are known to be upstream and controllers of T cells and NK cells, we have a significantly better chance of success."

The data disclosed in the filed patent application demonstrate that dendritic cells generated from iPSC cells expressing the BORIS antigen can induce regression of B16 melanoma, and that when the dendritic cells were generated from iPSC cells gene silenced for VEGF-receptor, a significantly stronger anti-tumor response was observed.

"Having pioneering leaders of cancer immunotherapy such as Drs. Francesco Marincola and Santosh Kesari provides incredible inspiration for our development of such "next generation" therapies such as StemVacs-V™," stated Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "The StemVacs-V platform is amenable not only to the BORIS antigen and VEGF-R gene silencing. We are in the process of testing various combination products as we ramp up this technology from preclinical and eventual clinical trials."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients

2 DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice

3 Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites

Contact: ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V™ iPSC Derived Cancer Immunotherapeutic

"Universal Donor" Gene Modified Dendritic Cell Based Therapy Concurrently Stimulates Adaptive and Innate Immunity in Animal Cancer Model


https://www.prnewswire.com/news-release ... 52742.html


ELK CITY, Idaho, March 22, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating its StemVacs-V iPSC derived dendritic cell product stimulates two distinct immunological mechanisms responsible for its anticancer activity in animal studies.

In a series of experiments, Company scientists observed that mice bearing B16 melanoma treated with StemVacs-V possessed an increased T cell response towards the tumor associated antigen Brother of the Regulator of Imprinted Sites. Additionally, examination of tumors regressing as a result of StemVacs-V treatment, revealed increased macrophage and natural killer cell infiltration. Depletion of either T cells or natural killer cells in treated mice abrogated the cancer-reducing activity of StemVacs-V.

"As we advance our stem derived product towards FDA filing, it is critical to demonstrate not only reproducible efficacy but also distinct mechanisms of action" said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "We are particularly excited by the dual mechanism of action displayed by StemVacs-V, suggesting possible advantages to other cancer therapies which usually only stimulate either adaptive or innate immunity."

"Although current immunotherapies such as checkpoint inhibitors have resulted in remissions in numerous types of advanced cancers, these approaches still fail to produce a meaningful response in tumors considered immunologically "cold"" said Famela Ramos, Vice President of Business Development for the Company. "Given that tumors which respond to checkpoint inhibitors are usually characterized by natural killer cell infiltration, we are currently exploring the possibility of utilizing StemVacs-V as a sensitizer for other FDA approved immunotherapies."

"We are extremely excited about the rapid rate our team is advancing the StemVacs-V product, which promises to be a type of immunotherapy that is: a) easy to produce in large quantities; b) can be tailored to specific biological characteristics of different cancers; and c) appears safe and highly potent in existing animal studies" said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels

Novel Strategy Demonstrates Potent Results in Animal Model of Lung Cancer through Fusing StemVacs-V™ Immunotherapy with In-Vitro Generated Cancer Blood Vessels


https://www.prnewswire.com/news-release ... 53715.html


ELK CITY, Idaho, March 23, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today filing of a patent with new data on a unique cell created by the Company capable of training the immune system to kill blood vessels feeding cancer, but sparing healthy blood vessels. These data are an extension of previous findings from the Company showing that StemVacs is capable of suppressing new blood vessel production.

"Killing malignant blood vessels is the basis for Avastin, an antibody-based drug which created 7 billion in revenue last year.1 Another company, Batu Biologics, previously demonstrated vaccination against cancer blood vessels is safe and was cleared by the FDA for clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company. "The approach developed by our Company is completely unique because it merges the potent antigen presenting capabilities of StemVacs-V together with the reproducibility and consistency of iPSC generated tumor-like endothelial cells."

StemVacs-V™ is comprised of "cancer resistant" dendritic cells which are developed from an engineered iPSC cell line. The novel chimeric cell product is generated by fusing StemVacs-V with iPSC derived endothelial cells which are cultured in a manner to make them replicate cancer stem cells. Proof of selective killing of cancer blood vessels was obtained by demonstration of immune response to proteins found only on cancer blood vessels.

"Numerous companies such as Fate Therapeutics, NantKwest, and Century Therapeutics have all achieved significant valuations through pioneering novel uses of iPSC derived immune cells," said Famela Ramos, Vice President of Business Development. "To our knowledge we are the first company to use iPSC derived cells to stimulate naturally occurring immunity to kill what some call the 'Achilles Heel' of cancer."

"Generation of a new cell that didn't previously exist is a significant milestone for our Company. We believe the current animal studies in lung cancer can be extrapolated to other cancers, since no cancer can grow more than 2 millimeters without creating new blood vessels," said Timothy Dixon, President and CEO of the Company and co-inventor of the patent. "By selectively killing cancer blood vessels the problem of mutations is solved since cancer blood vessels are not generated from tumor tissue and they do not mutate. Furthermore, since blood vessels are in direct contact with the blood and immune cells that travel through the blood, it is substantially easier for the immune system to kill malignant vessels as opposed to tumors."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

1 https://www.fiercepharma.com/special-re ... 19-avastin

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies

Clinical Stage Biotech Company Develops Third Immunotherapy Aimed at "Starving Cancer"


https://www.prnewswire.com/news-release ... 57387.html


ELK CITY, Idaho, March 29, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data and a new patent filing demonstrating this new immunotherapy derived from inducible pluripotent stem cells (iPSC) induces potent and selective killing of cancer associated blood vessels.

In contrast to other approaches, the current immunotherapy involves transfection of the enzyme alpha1,3-galactosyltransferase into the iPSC, following that iPSC cells are transformed into tumor endothelial-like cells and used for immunization. The introduction of the alpha1,3-galactosyltransferase gene causes the cells to express to Gal alpha 1-3Gal beta-4-GlcNAc (alpha Gal). Alpha Gal is one of the most potent immune stimulating molecules in nature, evoking one of the most potent immune responses known to man.

"Previous immunotherapies activate and recruit approximately 1 out of 1,000,000 immune cells to attack cancer whereas the current approach activates as much as 1 out of 100 immune cells," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "It is well known in the field of xenotransplantation that humans possess 1 to 5% of their antibodies directed towards the alpha Gal epitope which is found in all animals with the exception of monkeys and humans. This is God's way of stopping inter-species transplantation. By directing this potent antibody response against tumor blood vessels our preliminary data supports feasibility of this novel approach in attacking the Achilles heel of cancer, which is angiogenesis."

Side by side comparison between the currently described approach and approaches, such as placental derived cancer endothelial vaccines like ValloVax by Batu Biologics, suggest significantly higher level of immunity towards cancer angiogenesis can be obtained with the currently described approach.

"The advantage of using iPSC technology is that we are generating consistent and reproducible cell therapy products, which are two features essential for partnership with Big Pharma as well as progression through the regulatory process," said Famela Ramos, Vice President of Business Development. "What we are talking about here is the production of a Third Generation Cellular Immunotherapy for cancer."

"Our Company's philosophy has always been to leverage existing propensities of the body as opposed to fighting the body," stated Timothy Dixon, President and CEO of the Company and co-inventor. "I commend our collaborating scientists for the completely novel concept of leveraging existing premade antibodies as a new way of shutting down the formation of new blood vessels by the cancer."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE Therapeutic Solutions International
Related Links

http://www.therapeuticsolutionsint.com
trader32176
Posts: 2556
Joined: Fri Jun 26, 2020 5:22 am

Re: News Portal

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Efficacy of Kaihani Score in Prediction of Gambling Addiction

Suicide Prevention Company Succeeds in Utilizing Brain-Immune Connection to Quantifiably Assess Gambling Addiction Status


https://www.prnewswire.com/news-release ... 61934.html


ELK CITY, Idaho, April 5, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today completion of its 30-patient trial assessing the Kaihani Score blood-based test for gambling addiction.

The clinical trial, which as registered on the Federal Clinical Trials Database as Validation of Kaihani Score for Gambling Addiction1 showed a profound difference of a specific neuromodulatory protein between healthy controls (15.6±5.5 ng/ml), patients with moderate gambling addiction (34.8±11.2 ng/ml) and patients with severe gambling addiction (50.9±24.3 ng/ml). Severity of gambling addition was assessed using Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS).

"This data demonstrates the ability to assess psychological abnormalities using quantitative blood-based approaches" said Kalina O'Connor, President and CEO of Campbell Neurosciences. "It is our aim at Campbell Neurosciences to address the root causes of mental illnesses, and using this knowledge to develop cures, not band-aid drugs."

Campbell Neurosciences, a spin-off of the biotherapeutics company Therapeutic Solutions International is named after Kathleen Campbell, mother of Kalina O'Connor, who was a victim of suicide.

"In contrast to the Campbell Score™, which assesses inflammatory markers as a means of diagnosing suicidal ideations, the Kaihani Score™ assesses specific neuromodulatory peptides made by the brains of gambling addicts" said Dr. James Veltmeyer, Chief Medical Officer of the Company. "A completely different nature of the cytokines involved suggest the existence of complicated neuroimmune circuits. Our mission at Campbell is to decipher these circuits and develop practical interventions."

Ms. O'Connor recently published a manuscript outlining the contributions of the immune system to nervous system function with emphasis on mental illness Suicide: An Immunological Disorder?2

"The successful completion of this clinical trial indicates that we now have a potential new weapon in identifying who is at risk of gambling addition, which is the first step in conquering this epidemic which takes a $54 billion annual toll on our economy3" said Wais Kaihani, co-inventor of the Kaihani score and consultant to the Company.

"I congratulate Campbell Neurosciences and the excellent work their clinical team has performed in rapidly completing the second clinical trial this year demonstrating successful identification of mental illness using blood based immunological tests" stated Timothy Dixon, President and CEO of Therapeutic Solutions International and Co-Inventor of the Kaihani Score™.

The Company is currently engaging regulators in discussions with the aim of initiating a pivotal registration trial for both the Campbell Score and the Kaihani Score.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

1 Validation of Kaihani Score for Gambling Addiction
2 Suicide: An Immunological Disorder?
3 Social costs of gambling nearly half that of drug abuse, new book concludes

SOURCE Therapeutic Solutions International

Related Links

therapeuticsolutionsint.com
Post Reply